reports
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Car...
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will parti...
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometria...
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently disclosed promising results in serous EC, in the context of high unmet need in EC Panos Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, professor, Harvard Medical Schoo...
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics C...
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational and strategic benefits for internal and future partnered assets WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing ...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
SCL STEPAN COMPANY
RLI RLI CORP.
NBTB NBT BANCORP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
IPAR INTER PARFUMS INC.
IP INTERNATIONAL PAPER COMPANY
INTC INTEL CORPORATION
GME GAMESTOP CORP. CLASS A
CMC COMMERCIAL METALS COMPANY
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
PAR PAR TECHNOLOGY CORP.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ESQ ESQUIRE FINANCIAL HOLDINGS
ABT ABBOTT LABORATORIES
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
ANIX INC.
AMTB ANIXA BIOSCIENCES
CABA AMERANT BANCORP (A)
JYNT CABALETTA BIO
ALLY THE JOINT
ALT GMAC LLC
APG ALTIMMUNE INC
ZNTL API GROUP CORP
AVO ZENTALIS PHARMACEUTICALS
TMC MISSION PRODUCE
IMRX TMC THE METALS CO INC
BST IMMUNEERING CORP
LUCY BLACKROCK SCIENCE AND TECHNOLOGY TRUST
PMCB INNOVATIVE EYEWEAR INC
VANI PHARMACYTE BIOTECH INC
ACRV VIVANI MEDICAL INC
BOF ACRIVON THERAPEUTICS INC
SRBK BRANCHOUT FOOD INC.
WS WI SR BANCORP INC
GDV WORTHINGTON STEEL
GF THE GABELLI DIVIDEND & INCOME TRUST
CVM THE NEW GERMANY FUND
MSTR INC.
BDSX CEL-SCI CORPORATION
MPTI MICROSTRATEGY INCORPORATED
MIGI BIODESIX INC
SQNS M-TRON INDUSTRIES
INC.
MAWSON INFRASTRUCTURE GROUP INC
SEQUANS COMMUNICATIONS
- Jonathan Moreland
SCL STEPAN COMPANY
RLI RLI CORP.
LTC LTC PROPERTIES INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
IPAR INTER PARFUMS INC.
GME GAMESTOP CORP. CLASS A
DAKT DAKTRONICS INC.
CMC COMMERCIAL METALS COMPANY
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
WHF WHITEFIELD
ADC AGREE REALTY CORPORATION
PAR PAR TECHNOLOGY CORP.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ESQ NIKE INC. CLASS B
FGBI ESQUIRE FINANCIAL HOLDINGS
GRX FIRST GUARANTY BANCSHARES
CABA THE GABELLI HEALTHCARE & WELLNESSRX TRUST
JYNT CABALETTA BIO
ALLY THE JOINT
ALT GMAC LLC
APG ALTIMMUNE INC
ZNTL API GROUP CORP
AVO ZENTALIS PHARMACEUTICALS
IVFH MISSION PRODUCE
TMC INNOVATIVE FOOD HLDG
IMRX TMC THE METALS CO INC
LUCY IMMUNEERING CORP
PMCB INNOVATIVE EYEWEAR INC
GLSI PHARMACYTE BIOTECH INC
VANI GREENWICH LIFESCIENCES INC
ACRV VIVANI MEDICAL INC
SUNS ACRIVON THERAPEUTICS INC
GF SUNRISE REALTY TRUST
MSTR THE NEW GERMANY FUND
MPTI INC.
MIGI MICROSTRATEGY INCORPORATED
SQNS M-TRON INDUSTRIES
INC.
MAWSON INFRASTRUCTURE GROUP INC
SEQUANS COMMUNICATIONS
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upco...
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, will highlight company’s recent interim clinical data from the ongoing, registrational-intent Phase 2b study of ACR-368 in subjects with endometrial cancer WATERTOWN, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnolog...
- Jonathan Moreland
SCL STEPAN COMPANY
MOD MODINE MANUFACTURING COMPANY
LTC LTC PROPERTIES INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
DAKT DAKTRONICS INC.
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
WHF WHITEFIELD
ADC AGREE REALTY CORPORATION
PAR PAR TECHNOLOGY CORP.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ESQ NIKE INC. CLASS B
FGBI ESQUIRE FINANCIAL HOLDINGS
GRX FIRST GUARANTY BANCSHARES
JYNT THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ALT THE JOINT
APG ALTIMMUNE INC
ZNTL API GROUP CORP
IVFH ZENTALIS PHARMACEUTICALS
TMC INNOVATIVE FOOD HLDG
IMRX TMC THE METALS CO INC
WRB IMMUNEERING CORP
LUCY W.R. BERKLEY CORPORATION
PMCB INNOVATIVE EYEWEAR INC
GLSI PHARMACYTE BIOTECH INC
MAIA GREENWICH LIFESCIENCES INC
ACRV MAIA BIOTECHNOLOGY INC
SUNS ACRIVON THERAPEUTICS INC
GF SUNRISE REALTY TRUST
MSTR THE NEW GERMANY FUND
MPTI INC.
SQNS MICROSTRATEGY INCORPORATED
MIGI M-TRON INDUSTRIES
INC.
SEQUANS COMMUNICATIONS
MAWSON INFRASTRUCTURE GROUP INC
- Jonathan Moreland
America’s Car-Mart Advances SG&A Cost Control Strategy With Phase 2 St...
America’s Car-Mart Advances SG&A Cost Control Strategy With Phase 2 Store Consolidations Consolidates 13 additional locations to continue modernizing the business, better utilize inventory and teams, and strengthen performance at remaining locations. ROGERS, Ark., Jan. 13, 2026 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“Car-Mart” or the “Company”) today announced the completion of Phase 2 of its previously announced SG&A Cost Control Strategy through footprint optimization, which includes the consolidation of 13 locations into higher-performing nearby dealerships. Thi...
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial C...
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of ...
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase ...
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predic...
America’s Car-Mart, Inc. Completes $161.3 Million Term Securitization
America’s Car-Mart, Inc. Completes $161.3 Million Term Securitization New Residual Structure Improves Capital Efficiency ROGERS, Ark., Dec. 18, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart,” or the “Company”) announced today that it has completed a term securitization transaction involving the issuance of $161.3 million in principal amount of asset-backed notes with a weighted average coupon of 7.02%. The 2025-4 transaction marks another significant milestone for Car-Mart, as it introduces a more efficient deal structure that generates increased cas...
BRT Apartments Corp. Completes Debt Refinancings
BRT Apartments Corp. Completes Debt Refinancings GREAT NECK, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that it has successfully completed the refinancing of three mortgages mentioned in the Company’s most recent 10-Q filing. The three maturing mortgages in the aggregate amount of $42.7 million and bearing a weighted average interest rate of 4.36% were refinanced through new mortgage debt in the aggregate amount of approximately $71.9 million, with a weighted average remaining term to maturity of approximately nine years and a weighted averag...
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ong...
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global co...
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase ...
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-r...
BRT Apartments Corp. Announces Quarterly Dividend
BRT Apartments Corp. Announces Quarterly Dividend GREAT NECK, New York, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable January 6, 2026, to stockholders of record at the close of business on December 22, 2025. The Company estimates that for federal income tax purposes, all of this dividend will be included in 2026 taxable income and that all of the dividends paid in 2025 will be treated as a return of capital. BRT is a real estate investment trust that ...
America’s Car-Mart Reports Second Quarter Fiscal Year 2026 Results
America’s Car-Mart Reports Second Quarter Fiscal Year 2026 Results ROGERS, Ark., Dec. 04, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the second quarter ended October 31, 2025. Second Quarter Key Highlights (FY’26 Q2 vs. FY’25 Q2, unless otherwise noted) Closed $300.0 million term loan and repaid revolving line of credit balance, enhancing capital structure and expanding flexibility to support originations and operationsTotal cash, including restricted cash, increased to $251.0 million from $124...
- Jonathan Moreland
- Jonathan Moreland
RPD RAPID7 INC.
LOB LIVE OAK BANCSHARES
JACK JACK IN THE BOX INC.
HFWA HERITAGE FINANCIAL CORPORATION
EGBN EAGLE BANCORP INC.
DIN DINE BRANDS GLOBAL INC.
CLX CLOROX COMPANY
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
INSE INSPIRED ENTERTAINMENT
MLP MAUI LAND & PINEAPPLE CO. INC.
USPH U.S. PHYSICAL THERAPY
AEYE INC.
UTZ AUDIOEYE INC
AUID UTZ BRANDS INC (A)
NEXT IPSIDY INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
CWGL EVOLV TECHNOLOGIES HLDGS INC
QDEL CRIMSON WINE GROUP
WEST LTD
PROP QUIDEL CORP
SPRU WESTROCK COFFEE COMPANY LLC
GF PRAIRIE OPERATING CO.
NOV SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
NATIONAL OILWELL VARCO
INC. 
- MarketLine Department
Group 1 Automotive, Inc. - Mergers & Acquisitions (M&A), Partnerships ...
Summary Marketline's Group 1 Automotive, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Group 1 Automotive, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.